Martin Babler, Alumis CEO

Alu­mis clos­es a $259M Se­ries C to back its TYK2, flirts with talk about an IPO

As it pre­pares to launch Phase III stud­ies of its TYK2 in­hibitor, im­munol­o­gy start­up Alu­mis has raised a $259 mil­lion Se­ries C round that will fund the late-stage tri­als in mod­er­ate-to-se­vere plaque pso­ri­a­sis.

Alu­mis said piv­otal stud­ies for its drug ESK-001 will be­gin in the sec­ond half of this year. The Fore­site Labs-in­cu­bat­ed biotech hopes that the ex­per­i­men­tal ther­a­py could com­pete with Bris­tol My­ers Squibb’s So­tyk­tu and an up­com­ing drug from Take­da that was at the heart of one of last year’s biggest li­cens­ing deals.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.